Evidence map›Paper›PMID 21561376›Full record

ArticleAssay and drug development technologies2011

High-throughput screen for the chemical inhibitors of antiapoptotic bcl-2 family proteins by multiplex flow cytometry.

Ramona F Curpan, Peter C Simons, Dayong Zhai, Susan M Young, Mark B Carter, Cristian G Bologa, Tudor I Oprea, Arnold C Satterthwait, John C Reed, Bruce S Edwards and 1 more

Open access · greenAbstract read
In one paragraph

Article in Assay and drug development technologies, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Flow Cytometry: Impact on Early Drug Discovery.Journal of biomolecular screening · 2015
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Cluster cytometry for high-capacity bioanalysis.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2012
    Article
  13. Drug Repurposing from an Academic Perspective.Drug discovery today. Therapeutic strategies · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Ramona F CurpanComputational Chemistry Group, Romanian Academy Institute of Chemistry, Timisoara, Romania.
Peter C Simons
Dayong Zhai
Susan M Young
Mark B Carter
Cristian G Bologa
Tudor I Oprea
Arnold C Satterthwait
John C Reed
Bruce S Edwards
Larry A Sklar
University of New Mexico · USSanford Burnham Prebys Medical Discovery Institute · USRomanian Academy · RO

Funding

New Mexico Molecular Libraries Screening Center(RMI)U54MH074425 · NIMH · UNIVERSITY OF NEW MEXICO · PI SKLAR, LARRY A. · 2005 to 2008
$10.0M
NIMH NIH HHS U54MH074425
6 · The paper itself

Abstract

The human Bcl-2 family includes six antiapoptotic members (Bcl-2, Bcl-B, Bcl-W, Bcl-X(L), Bfl-1, and Mcl-1) and many proapoptotic members, wherein a balance between the two determines cell life or death in many physiological and disease contexts. Elevated expression of various antiapoptotic Bcl-2 members is commonly observed in cancers, and chemical inhibitors of these proteins have been shown to promote apoptosis of malignant cells in culture, in animal models, and in human clinical trials. All six antiapoptotic members bind a helix from the proapoptotic family member Bim, thus quenching Bim's apoptotic signal. Here, we describe the use of a multiplex, high-throughput flow cytometry assay for the discovery of small molecule modulators that disrupt the interaction between the antiapoptotic members of the Bcl-2 family and Bim. The six antiapoptotic Bcl-2 family members were expressed as glutathione-S-transferase fusion proteins and bound individually to six glutathione bead sets, with each set having a different intensity of red fluorescence. A fluorescein-conjugated Bcl-2 homology region 3 (BH3) peptide from Bim was employed as a universal ligand. Flow cytometry measured the amount of green peptide bound to each bead set in a given well, with inhibitory compounds resulting in a decrease of green fluorescence on one or more bead set(s). Hits and cheminformatically selected analogs were retested in a dose-response series, resulting in three "active" compounds for Bcl-B. These three compounds were validated by fluorescence polarization and isothermal titration calorimetry. We discuss some of the lessons learned about screening a chemical library provided by the National Institutes of Health Small Molecule Repository (∼195,000 compounds) using high-throughput flow cytometry.

Indexed as

AnimalsApoptosisApoptosis Regulatory ProteinsBcl-2-Like Protein 11Binding, CompetitiveCalorimetryClinical Trials as TopicDose-Response Relationship, DrugDrug DiscoveryDrug Evaluation, PreclinicalFlow CytometryFluorescence PolarizationGlutathioneGreen Fluorescent ProteinsHigh-Throughput Screening AssaysHumansApoptosis Regulatory ProteinsBCL2L11 protein, humanBcl-2-Like Protein 11GlutathioneGreen Fluorescent ProteinsMembrane ProteinsProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-2Small Molecule Libraries

Identifiers

PMID21561376
PMCPMC3182036
OpenAlexW1996473329

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.